Comparison of the microarray-based assay, the real-time PCR assay, and the bidirectional sequencing method for CYP2C19 genotyping

Hyun Ki Kim, Hyun Jung Kang, Dae Hyun Ko, Tae Dong Jeong, Woochang Lee, Sail Chun, Won Ki Min

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: Cytochrome P450 2C19 (CYP2C19) is a clinically important enzyme that metabolizes a wide variety of drugs. Recently, some new genetic assays designed to identify the CYP2C19 genotype were introduced. Methods: We compared the abilities of the microarray-based Verigene CYP2C19 Test (Nanosphere, USA) and the AccuPower Real-time PCR CYP (2,3,17) assay (Bioneer, Korea) with the ability of the bidirectional sequencing method for the detection of CYP2C19 genotypes in 78 whole blood samples. Results: Among 78 specimens, 28 were 1/1, 1 was 1/17, 27 were 1/2, 10 were 1/3, 8 were 2/2, 1 was 3/3, and 3 were 2/3. In the initial test, five samples (6.4%) in the Verigene assay and two samples (2.4%) in the AccuPower assay failed to generate definite results. All retests with both assays generated definitive results. In both assays, the results of CYP2C19 genotyping showed 100% final concordance with those obtained by the direct sequencing method. Conclusions: These two assays could be useful for the identification of CYP2C19 genotypes in clinical laboratories.

Original languageEnglish
Pages (from-to)1109-1112
Number of pages4
JournalClinical Laboratory
Volume61
Issue number8
DOIs
StatePublished - 2015

Keywords

  • CYP2C19
  • Genotyping
  • Microarray
  • Real-time polymerase chain reaction

Fingerprint

Dive into the research topics of 'Comparison of the microarray-based assay, the real-time PCR assay, and the bidirectional sequencing method for CYP2C19 genotyping'. Together they form a unique fingerprint.

Cite this